Trial
NCT02704403
Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Genfit
Collaborators
—
Condition
Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Intervention
Elafibranor
Why stopped
Study did not meet the predefined primary surrogate efficacy endpoint, no safety issues identified
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-03-23